Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.53 |
| ▸ | REN | P00797 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060490 | 0.96 | CTSS (0.56) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL1032021 | 0.96 | CTSS (0.56) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3171386 | 0.96 | CTSS (0.56) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL23771874 | 0.90 | CTSS (0.53) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18206853 | 0.88 | CTSS (0.50) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18206856 | 0.88 | CTSS (0.50) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18206854 | 0.88 | CTSS (0.50) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL22929153 | 0.87 | BCL2 (0.56) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL10723853 | 0.86 | CTSS (0.55) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL3750286 | 0.86 | CTSS (0.55) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ZEVRA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | ZEVRA THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | ALTER DOMUS (US) LLC | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012384-B2 | Dextrorphan prodrugs and processes for making and using them | OGFR, OPRM1, CYP4F3 | CTSS 1147/4885CTSK 2342/4885CTSB 1745/4885 |
| US-12590065-B2 | Levorphanol prodrugs and processes for making and using them | SLC16A3, SLC16A8, SLC16A1 | CTSS 1409/4885CTSK 2835/4885CTSB 1271/4885 |
| US-20240317688-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OPRM1, OPRL1, OGFR | CTSS 1058/4885CTSK 1902/4885CTSB 1492/4885 |
| US-20220089544-A1 | DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM | OGFR, OPRM1, CYP4F3 | CTSS 1147/4885CTSK 2342/4885CTSB 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.